Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrocortisone + bacitracin + colistin is a topical otic combination formulation consisting of a corticosteroid and two antibiotics. Hydrocortisone serves as an anti-inflammatory agent to reduce swelling and pain in the ear canal. Bacitracin is a polypeptide antibiotic that inhibits bacterial cell wall synthesis by binding to undecaprenyl pyrophosphate, while colistin is a polymyxin antibiotic that disrupts bacterial cell membranes by binding to lipopolysaccharides. This combination is primarily used for the treatment of acute otitis media with ear discharge (AOMd) and otorrhea, targeting pathogens such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Pseudomonas aeruginosa*. It is notably used in the Netherlands and France, often as an alternative to oral antibiotics or aminoglycoside-containing eardrops to avoid potential ototoxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone + bacitracin + colistin.